预防心血管事件和死亡与普伐他汀对冠心病患者和广泛的最初的胆固醇水平。
文章的细节
-
引用
复制到剪贴板 -
作者不明
预防心血管事件和死亡与普伐他汀对冠心病患者和广泛的最初的胆固醇水平。
郑传经地中海J。1998年11月5日,339 (19):1349 - 57。doi: 10.1056 / NEJM199811053391902。
- PubMed ID
-
9841303 (在PubMed]
- 文摘
-
背景:冠心病患者和广泛的胆固醇水平,降胆固醇治疗可以减少冠状动脉事件的风险,但对死亡率的影响冠心病和总体死亡率仍不确定。方法:在一个双盲随机试验,我们比较普伐他汀的影响与安慰剂(40毫克每天)在9014年的平均6.1年的随访期间患者31到75岁。心肌梗死的病人有历史或住院治疗不稳定心绞痛和初始血浆总胆固醇水平的155到271毫克/分升。两组收到建议后降胆固醇的饮食。主要的研究结果是冠心病的死亡率。结果:死于冠心病发生在安慰剂组8.3%的患者和6.4%的普伐他汀组,相对风险降低24%(95%置信区间,12 - 35%;P < 0.001)。整体死亡率为14.1%,安慰剂组11.0%,普伐他汀组(相对风险,减少22%;95%置信区间,13至31%;P < 0.001)。 The incidence of all cardiovascular outcomes was consistently lower among patients assigned to receive pravastatin; these outcomes included myocardial infarction (reduction in risk, 29 percent; P<0.001), death from coronary heart disease or nonfatal myocardial infarction (a 24 percent reduction in risk, P<0.001), stroke (a 19 percent reduction in risk, P=0.048), and coronary revascularization (a 20 percent reduction in risk, P<0.001). The effects of treatment were similar for all predefined subgroups. There were no clinically significant adverse effects of treatment with pravastatin. CONCLUSIONS: Pravastatin therapy reduced mortality from coronary heart disease and overall mortality, as compared with the rates in the placebo group, as well as the incidence of all prespecified cardiovascular events in patients with a history of myocardial infarction or unstable angina who had a broad range of initial cholesterol levels.
DrugBank数据引用了这篇文章
- 药物